References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
- Cauley J A, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729–1738
- Board of the International Menopause Society, Pines A, Sturdee D W, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181–194
- Rossouw J E, Prentice R L, Manson J E, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–1477
- Panay N, Ylikorkala O, Archer D F, et al. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007; 10: 120–131
- Rioux J E, Devlin M C, Gelfand M M, et al. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000; 7: 156–161
- Gompel A, Barlow D, Rozenberg S, et al. The EMAS 2006/2007 update on clinical recommendations on postmenopausal hormone therapy. Maturitas 2007; 56: 227–229
- North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 168–182
- International Menopause Society. New data on hormone therapy must lead to re-evaluation of official guidelines: a plea for health authorities. September 30, 2007. http://www.imsociety.org/downloads/ims_plea.pdf
- Pines A, Sturdee W, MacLennan A, et al. The heart of the WHI study: time for hormone therapy policies to be revised. Climacteric 2007; 10: 267–269
- Andersson K, Mattsson L A, Milsom I. Use of hormone replacement therapy. Lancet 1996; 348: 1521